Binding affinity to HSP90 in human HCT116 cells assessed as increase in staining intensity in cytosol at 5 uM after 72 hrs by immunofluorescence staining analysis
Competitive binding affinity to N-middle domain of HSP90 expressed in BL21(DE)3 Escherichia coli cells after 1 hr by immunoblotting analysis in the presence of 2-chlorobenzyl 4-((2R,5S,8S,11S,14R)-11,14-dibenzyl-8-isobutyl-5-isopropyl-13-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)butylcarbamate
Binding affinity to human Hsp90 assessed as inhibition of interaction with His/GST-tagged recombinant co-chaperone TOM70 up to 10 uM preincubated for 1 hr followed by co-chaperone addition measured after 1 hr by Western blotting analysis
Binding affinity to human Hsp90 assessed as inhibition of interaction with His/GST-tagged recombinant co-chaperone CHIP up to 10 uM preincubated for 1 hr followed by co-chaperone addition measured after 1 hr by Western blotting analysis
Binding affinity to human Hsp90 assessed as inhibition of interaction with His/GST-tagged recombinant co-chaperone Unc45 up to 10 uM preincubated for 1 hr followed by co-chaperone addition measured after 1 hr by Western blotting analysis
Binding affinity to human Hsp90 assessed as inhibition of interaction with His/GST-tagged recombinant co-chaperone CYP40 up to 10 uM preincubated for 1 hr followed by co-chaperone addition measured after 1 hr by Western blotting analysis
Inhibition of Hsp90 in human HeLa cells assessed as downregulation of FKBP52 protein level at 40 uM after 30 hours by Western blotting analysis in presence of proteasome inhibitor MG-132
Inhibition of Hsp90 in human HeLa cells assessed as downregulation of FKBP51 protein level at 40 uM after 30 hours by Western blotting analysis in presence of proteasome inhibitor MG-132
Inhibition of Hsp90 in human HeLa cells assessed as downregulation of glucocorticoid receptor protein level at 5 to 50 uM after 30 hours by Western blotting analysis relative to DMSO-treated control
Inhibition of Hsp90 in human HeLa cells assessed as change in glucocorticoid receptor protein level at 0.1 to 1 uM after 30 hours by Western blotting analysis
Inhibition of Hsp90 in human HeLa cells assessed as upregulation of FKBP51 protein level at 0.1 to 1 uM after 30 hours by Western blotting analysis relative to DMSO-treated control
Inhibition of Hsp90 in human HeLa cells assessed as upregulation of FKBP52 protein level at 0.1 to 1 uM after 30 hours by Western blotting analysis relative to DMSO-treated control
Inhibition of Hsp90 in human HeLa cells assessed as downregulation of FKBP51 protein level at 5 to 50 uM after 30 hours by Western blotting analysis relative to DMSO-treated control
Inhibition of Hsp90 in human HeLa cells assessed as downregulation of FKBP52 protein level at 5 to 50 uM after 30 hours by Western blotting analysis relative to DMSO-treated control
Inhibition of Hsp90 in human HeLa cells assessed as downregulation of glucocorticoid receptor protein level at 40 uM after 30 hours by Western blotting analysis in presence of proteasome inhibitor MG-132
Binding affinity to human Hsp90 assessed as inhibition of interaction with His/GST-tagged recombinant co-chaperone TOM70 at 5 uM preincubated for 1 hr followed by co-chaperone addition measured after 1 hr by Western blotting analysis
Binding affinity to human Hsp90 assessed as inhibition of interaction with His/GST-tagged recombinant co-chaperone FKBP51 at 5 uM preincubated for 1 hr followed by co-chaperone addition measured after 1 hr by Western blotting analysis
Inhibition of Hsp90 in human HeLa cells assessed as downregulation of HSF1 protein expression at 5 uM to 50 uM after 30 hours by Western blotting analysis relative to DMSO-treated control